- Biocon Biologics marks its first anniversary as a fully integrated global biosimilars company.
- The company operates in over 120 countries, focusing on affordable biologic medicines.
Unlock the Full Filing And Lot More
Access premium insights and stay ahead of the market with Dzambhala Pro.
Learn More
BIOCON PRIOR FILINGS
- 13h ago
- 2d ago
- 5d ago
- 5d ago
- 6d ago
Biocon Engages Institutional Investor Quest Investment Advisors in Virtual Meeting, No UPSI Disclos…
Biocon Gets Approval for Ustekinumab BS Biosimilar in Japan, Expanding Global Presence
Biocon To Hold Q3 FY 2024-25 Earnings Call on January 31, Trading Window Closed Until February 1
Biocon To Approve Q3 FY 2024-25 Financial Results In Board Meeting On January 30, Trading Window Cl…
Biocon Pharma Gets NMPA Approval for Tacrolimus Capsules, Expanding Its Drug Portfolio in China
ALL LATEST FILINGS
- 40m ago
- 11h ago
- 11h ago
- 12h ago
- 13h ago
Novelis, Hindalco's Subsidiary, Upsizes Senior Notes Offering to $750 Million to Strengthen Financi…
HDFC Life To Host Earnings Call On January 15 To Discuss 9M FY25 Financial Performance
HCL Technologies To Announce Q3 FY 2025 Financial Results on January 13, Followed by Conference Call
Kotak Mahindra Bank To Review Q3 Financial Results and Consider Fundraising Proposal in Board Meeti…
Biocon Engages Institutional Investor Quest Investment Advisors in Virtual Meeting, No UPSI Disclos…